Liver Disease Newco Alentis Raises CHF12.5m Series A
Executive Summary
A syndicate of European VCs commits CHF12.5m to Alentis Therapeutics a Swiss-French start-up with a discovery platform focusing on liver diseases. Lead program is a humanized monoclonal antibody targeting liver fibrosis and hepatocellular carcinoma.
You may also be interested in...
Alentis Aims To Put The Brakes On Fibrosis
Building on 20 years of work and positive preclinical data, and backed by a fresh injection of cash, Alentis is taking its liver fibrosis candidate into Phase I trials in the fourth quarter.
Finance Watch: New Funding Available For Antibacterials, Start-Ups
Private Company Edition: The Novo Holdings Repair Impact Fund wants to fund another round of antimicrobial resistance efforts. Also, Atlas Venture raised a new $400m fund, Everest closed a $310m series C round and Cognition received a $78.5m grant.
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.